At EQL Pharma’s Annual General Meeting, which was held today in Lund, August 22nd, 2019, the following decisions were made:
Adoption of the balance sheet and income statement, disposition regarding the Company’s results
The annual general meeting resolved to adopt the balance sheet and income statement and the consolidated balance sheet and income statement for the financial year 2018-04-01 – 2019-03-31. The annual general meeting also resolved that no dividends shall be paid for the financial year 2018/2019.
Discharge from liability for the Board of Directors and the Managing Director